ID   LX15B_HUMAN             Reviewed;         676 AA.
AC   O15296; D3DTR2; Q8IYQ2; Q8TEV3; Q8TEV4; Q8TEV5; Q8TEV6; Q9UKM4;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   15-MAR-2017, entry version 165.
DE   RecName: Full=Arachidonate 15-lipoxygenase B;
DE            Short=15-LOX-B;
DE            EC=1.13.11.33;
DE   AltName: Full=15-lipoxygenase 2;
DE            Short=15-LOX-2;
DE   AltName: Full=Arachidonate 15-lipoxygenase type II;
DE   AltName: Full=Linoleate 13-lipoxygenase 15-LOb;
DE            EC=1.13.11.-;
GN   Name=ALOX15B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), VARIANT ARG-656, CATALYTIC
RP   ACTIVITY, AND TISSUE SPECIFICITY.
RC   TISSUE=Skin;
RX   PubMed=9177185; DOI=10.1073/pnas.94.12.6148;
RA   Brash A.R., Boeglin W.E., Chang M.S.;
RT   "Discovery of a second 15S-lipoxygenase in humans.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:6148-6152(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT ARG-656, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11350124; DOI=10.1006/geno.2001.6519;
RA   Krieg P., Marks F., Fuerstenberger G.;
RT   "A gene cluster encoding human epidermis-type lipoxygenases at
RT   chromosome 17p13.1: cloning, physical mapping, and expression.";
RL   Genomics 73:323-330(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A; B; C AND D), VARIANTS HIS-486
RP   AND ARG-656, AND FUNCTION IN CELL CYCLE PROGRESSION.
RX   PubMed=11839751; DOI=10.1074/jbc.M111936200;
RA   Tang S., Bhatia B., Maldonado C.J., Yang P., Newman R.A., Liu J.,
RA   Chandra D., Traag J., Klein R.D., Fischer S.M., Chopra D., Shen J.,
RA   Zhau H.E., Chung L.W.K., Tang D.G.;
RT   "Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle
RT   regulator in normal prostate epithelial cells.";
RL   J. Biol. Chem. 277:16189-16201(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A), AND VARIANT
RP   ARG-656.
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 337-484, ALTERNATIVE SPLICING
RP   (ISOFORMS A AND D), CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   KINETIC PARAMETERS, PATHWAY, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=10542053; DOI=10.1046/j.1432-1327.1999.00818.x;
RA   Kilty I., Logan A., Vickers P.J.;
RT   "Differential characteristics of human 15-lipoxygenase isozymes and a
RT   novel splice variant of 15S-lipoxygenase.";
RL   Eur. J. Biochem. 266:83-93(1999).
RN   [8]
RP   FUNCTION AS A 15S-LIPOXYGENASE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   ASP-602 AND VAL-603.
RX   PubMed=10625675; DOI=10.1074/jbc.275.2.1287;
RA   Jisaka M., Kim R.B., Boeglin W.E., Brash A.R.;
RT   "Identification of amino acid determinants of the positional
RT   specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2.";
RL   J. Biol. Chem. 275:1287-1293(2000).
RN   [9]
RP   FUNCTION IN CELL PROLIFERATION, AND SUBCELLULAR LOCATION.
RX   PubMed=12704195; DOI=10.1074/jbc.M301920200;
RA   Bhatia B., Maldonado C.J., Tang S., Chandra D., Klein R.D., Chopra D.,
RA   Shappell S.B., Yang P., Newman R.A., Tang D.G.;
RT   "Subcellular localization and tumor-suppressive functions of 15-
RT   lipoxygenase 2 (15-LOX2) and its splice variants.";
RL   J. Biol. Chem. 278:25091-25100(2003).
RN   [10]
RP   FUNCTION.
RX   PubMed=16112079; DOI=10.1016/j.bbrc.2005.08.029;
RA   Jisaka M., Iwanaga C., Takahashi N., Goto T., Kawada T., Yamamoto T.,
RA   Ikeda I., Nishimura K., Nagaya T., Fushiki T., Yokota K.;
RT   "Double dioxygenation by mouse 8S-lipoxygenase: specific formation of
RT   a potent peroxisome proliferator-activated receptor alpha agonist.";
RL   Biochem. Biophys. Res. Commun. 338:136-143(2005).
RN   [11]
RP   FUNCTION IN CYTOKINE SECRETION.
RX   PubMed=18067895; DOI=10.1016/j.atherosclerosis.2007.10.027;
RA   Danielsson K.N., Rydberg E.K., Ingelsten M., Akyuerek L.M.,
RA   Jirholt P., Ullstroem C., Forsberg G.B., Boren J., Wiklund O.,
RA   Hulten L.M.;
RT   "15-Lipoxygenase-2 expression in human macrophages induces chemokine
RT   secretion and T cell migration.";
RL   Atherosclerosis 199:34-40(2008).
RN   [12]
RP   INDUCTION BY UV.
RX   PubMed=18755188; DOI=10.1016/j.febslet.2008.08.017;
RA   Yoo H., Jeon B., Jeon M.S., Lee H., Kim T.Y.;
RT   "Reciprocal regulation of 12- and 15-lipoxygenases by UV-irradiation
RT   in human keratinocytes.";
RL   FEBS Lett. 582:3249-3253(2008).
RN   [13]
RP   FUNCTION.
RX   PubMed=22912809; DOI=10.1371/journal.pone.0043142;
RA   Magnusson L.U., Lundqvist A., Karlsson M.N., Skalen K., Levin M.,
RA   Wiklund O., Boren J., Hulten L.M.;
RT   "Arachidonate 15-lipoxygenase type B knockdown leads to reduced lipid
RT   accumulation and inflammation in atherosclerosis.";
RL   PLoS ONE 7:E43142-E43142(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.63 ANGSTROMS) IN COMPLEX WITH CALCIUM AND
RP   IRON, CATALYTIC ACTIVITY, COFACTOR, FUNCTION, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF ASP-39; GLU-44 AND ASP-85.
RX   PubMed=24497644; DOI=10.1074/jbc.M113.543777;
RA   Kobe M.J., Neau D.B., Mitchell C.E., Bartlett S.G., Newcomer M.E.;
RT   "The structure of human 15-lipoxygenase-2 with a substrate mimic.";
RL   J. Biol. Chem. 289:8562-8569(2014).
CC   -!- FUNCTION: Non-heme iron-containing dioxygenase that catalyzes the
CC       stereo-specific peroxidation of free and esterified
CC       polyunsaturated fatty acids generating a spectrum of bioactive
CC       lipid mediators. Converts arachidonic acid to 15S-
CC       hydroperoxyeicosatetraenoic acid/(15S)-HPETE. Also acts on
CC       linoleic acid to produce 13-hydroxyoctadecadienoic acid/13-HPODE.
CC       Has no detectable 8S-lipoxygenase activity but reacts with (8S)-
CC       HPETE to produce (8S,15S)-diHPETE. May regulate progression
CC       through the cell cycle and cell proliferation. May also regulate
CC       cytokine secretion by macrophages and therefore play a role in the
CC       immune response. May also regulate macrophage differentiation into
CC       proatherogenic foam cells. {ECO:0000269|PubMed:10625675,
CC       ECO:0000269|PubMed:11839751, ECO:0000269|PubMed:12704195,
CC       ECO:0000269|PubMed:16112079, ECO:0000269|PubMed:18067895,
CC       ECO:0000269|PubMed:22912809, ECO:0000269|PubMed:24497644}.
CC   -!- CATALYTIC ACTIVITY: Arachidonate + O(2) = (5Z,8Z,11Z,13E)-(15S)-
CC       15-hydroperoxyicosa-5,8,11,13-tetraenoate.
CC   -!- CATALYTIC ACTIVITY: Linoleate + O(2) = (9Z,11E)-13-
CC       hydroxyoctadeca-9,11-dienoate.
CC   -!- COFACTOR:
CC       Name=Fe cation; Xref=ChEBI:CHEBI:24875;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00726,
CC         ECO:0000269|PubMed:24497644};
CC       Note=Binds 1 Fe cation per subunit. {ECO:0000255|PROSITE-
CC       ProRule:PRU00726, ECO:0000269|PubMed:24497644};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1100 uM for arachidonate (isoform D at pH 7.4 and 20 degrees
CC         Celsius) {ECO:0000269|PubMed:10542053};
CC         KM=10 uM for linoleate (isoform A at pH 7.4 and 20 degrees
CC         Celsius) {ECO:0000269|PubMed:10542053};
CC         KM=25 uM for arachidonate (isoform A at pH 7.4 and 20 degrees
CC         Celsius) {ECO:0000269|PubMed:10542053};
CC         Vmax=4 umol/min/mg enzyme with arachidonate as substrate
CC         (isoform A at pH 7.4 and 20 degrees Celsius)
CC         {ECO:0000269|PubMed:10542053};
CC         Vmax=2 umol/min/mg enzyme with arachidonate as substrate
CC         (isoform D at pH 7.4 and 20 degrees Celsius)
CC         {ECO:0000269|PubMed:10542053};
CC         Vmax=4 umol/min/mg enzyme with linoleate as substrate (isoform A
CC         at pH 7.4 and 20 degrees Celsius) {ECO:0000269|PubMed:10542053};
CC   -!- PATHWAY: Lipid metabolism; hydroperoxy eicosatetraenoic acid
CC       biosynthesis. {ECO:0000269|PubMed:10542053}.
CC   -!- SUBCELLULAR LOCATION: Isoform A: Nucleus. Note=Other isoforms are
CC       excluded from the nucleus.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane.
CC       Cytoplasm, cytoskeleton. Membrane; Peripheral membrane protein.
CC       Note=Predominantly cytosolic; becomes enriched at membranes upon
CC       calcium binding.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=A; Synonyms=15-LOb1;
CC         IsoId=O15296-1; Sequence=Displayed;
CC       Name=B; Synonyms=15-LOX2sv-b;
CC         IsoId=O15296-2; Sequence=VSP_003142, VSP_003143;
CC       Name=C; Synonyms=15-LOX2sv-c;
CC         IsoId=O15296-3; Sequence=VSP_003144, VSP_003145;
CC       Name=D; Synonyms=15-LOX2sv-a, 15-LOb2;
CC         IsoId=O15296-4; Sequence=VSP_003142;
CC   -!- TISSUE SPECIFICITY: Expressed in hair, prostate, lung, ovary,
CC       lymph node, spinal cord and cornea. {ECO:0000269|PubMed:10542053,
CC       ECO:0000269|PubMed:11350124, ECO:0000269|PubMed:9177185}.
CC   -!- INDUCTION: Up-regulated by UV-irradiation.
CC       {ECO:0000269|PubMed:18755188}.
CC   -!- DOMAIN: The PLAT domain can bind calcium ions; this promotes
CC       association with membranes.
CC   -!- SIMILARITY: Belongs to the lipoxygenase family. {ECO:0000305}.
CC   -!- CAUTION: Despite its homology with mouse Alox8 (AC O35936), it
CC       seems not to have any 8S-lipoxygenase activity on arachidonate.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD37786.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U78294; AAB61706.1; -; mRNA.
DR   EMBL; AJ305028; CAC34521.1; -; Genomic_DNA.
DR   EMBL; AJ305029; CAC34521.1; JOINED; Genomic_DNA.
DR   EMBL; AJ305030; CAC34521.1; JOINED; Genomic_DNA.
DR   EMBL; AJ305031; CAC34521.1; JOINED; Genomic_DNA.
DR   EMBL; AF468051; AAL76274.1; -; mRNA.
DR   EMBL; AF468052; AAL76275.1; -; mRNA.
DR   EMBL; AF468053; AAL76276.1; -; mRNA.
DR   EMBL; AF468054; AAL76277.1; -; mRNA.
DR   EMBL; AC129492; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90098.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90100.1; -; Genomic_DNA.
DR   EMBL; BC035217; AAH35217.1; -; mRNA.
DR   EMBL; BC063647; AAH63647.1; -; mRNA.
DR   EMBL; AF149095; AAD37786.1; ALT_SEQ; Genomic_DNA.
DR   CCDS; CCDS11128.1; -. [O15296-1]
DR   CCDS; CCDS32558.1; -. [O15296-4]
DR   CCDS; CCDS32559.1; -. [O15296-2]
DR   RefSeq; NP_001034219.1; NM_001039130.1. [O15296-4]
DR   RefSeq; NP_001034220.1; NM_001039131.1. [O15296-2]
DR   RefSeq; NP_001132.2; NM_001141.2. [O15296-1]
DR   UniGene; Hs.111256; -.
DR   PDB; 4NRE; X-ray; 2.63 A; A=1-676.
DR   PDBsum; 4NRE; -.
DR   ProteinModelPortal; O15296; -.
DR   SMR; O15296; -.
DR   BioGrid; 106748; 8.
DR   IntAct; O15296; 3.
DR   STRING; 9606.ENSP00000369530; -.
DR   BindingDB; O15296; -.
DR   ChEMBL; CHEMBL2457; -.
DR   GuidetoPHARMACOLOGY; 1389; -.
DR   SwissLipids; SLP:000000651; -.
DR   SwissLipids; SLP:000001469; -. [O15296-1]
DR   SwissLipids; SLP:000001470; -. [O15296-4]
DR   iPTMnet; O15296; -.
DR   PhosphoSitePlus; O15296; -.
DR   BioMuta; ALOX15B; -.
DR   PaxDb; O15296; -.
DR   PeptideAtlas; O15296; -.
DR   PRIDE; O15296; -.
DR   DNASU; 247; -.
DR   Ensembl; ENST00000380173; ENSP00000369520; ENSG00000179593. [O15296-4]
DR   Ensembl; ENST00000380183; ENSP00000369530; ENSG00000179593. [O15296-1]
DR   Ensembl; ENST00000573359; ENSP00000460332; ENSG00000179593. [O15296-2]
DR   GeneID; 247; -.
DR   KEGG; hsa:247; -.
DR   UCSC; uc002gju.4; human. [O15296-1]
DR   CTD; 247; -.
DR   DisGeNET; 247; -.
DR   GeneCards; ALOX15B; -.
DR   H-InvDB; HIX0027139; -.
DR   HGNC; HGNC:434; ALOX15B.
DR   HPA; HPA010562; -.
DR   MIM; 603697; gene.
DR   neXtProt; NX_O15296; -.
DR   OpenTargets; ENSG00000179593; -.
DR   PharmGKB; PA24725; -.
DR   eggNOG; ENOG410IF0U; Eukaryota.
DR   eggNOG; ENOG410YN4N; LUCA.
DR   GeneTree; ENSGT00550000074415; -.
DR   HOVERGEN; HBG005150; -.
DR   InParanoid; O15296; -.
DR   KO; K08022; -.
DR   OMA; LVLPYTY; -.
DR   OrthoDB; EOG091G04A4; -.
DR   PhylomeDB; O15296; -.
DR   TreeFam; TF105320; -.
DR   BRENDA; 1.13.11.33; 2681.
DR   Reactome; R-HSA-2142770; Synthesis of 15-eicosatetraenoic acid derivatives.
DR   UniPathway; UPA00881; -.
DR   ChiTaRS; ALOX15B; human.
DR   GeneWiki; ALOX15B; -.
DR   GenomeRNAi; 247; -.
DR   PRO; PR:O15296; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000179593; -.
DR   CleanEx; HS_ALOX15B; -.
DR   ExpressionAtlas; O15296; baseline and differential.
DR   Genevisible; O15296; HS.
DR   GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0019898; C:extrinsic component of membrane; IDA:UniProtKB.
DR   GO; GO:0005622; C:intracellular; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0050473; F:arachidonate 15-lipoxygenase activity; IDA:UniProtKB.
DR   GO; GO:0036403; F:arachidonate 8(S)-lipoxygenase activity; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IDA:UniProtKB.
DR   GO; GO:0016165; F:linoleate 13S-lipoxygenase activity; IDA:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0051122; P:hepoxilin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0043651; P:linoleic acid metabolic process; IEA:Ensembl.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:UniProtKB.
DR   GO; GO:0019372; P:lipoxygenase pathway; TAS:Reactome.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; TAS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045926; P:negative regulation of growth; IDA:UniProtKB.
DR   GO; GO:0090197; P:positive regulation of chemokine secretion; IMP:UniProtKB.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IMP:UniProtKB.
DR   GO; GO:0035360; P:positive regulation of peroxisome proliferator activated receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030850; P:prostate gland development; NAS:UniProtKB.
DR   GO; GO:0030856; P:regulation of epithelial cell differentiation; NAS:UniProtKB.
DR   Gene3D; 2.60.60.20; -; 1.
DR   InterPro; IPR000907; LipOase.
DR   InterPro; IPR013819; LipOase_C.
DR   InterPro; IPR020834; LipOase_CS.
DR   InterPro; IPR020833; LipOase_Fe_BS.
DR   InterPro; IPR001885; LipOase_mml.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   PANTHER; PTHR11771; PTHR11771; 1.
DR   Pfam; PF00305; Lipoxygenase; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   PRINTS; PR00087; LIPOXYGENASE.
DR   PRINTS; PR00467; MAMLPOXGNASE.
DR   SMART; SM00308; LH2; 1.
DR   SUPFAM; SSF48484; SSF48484; 1.
DR   SUPFAM; SSF49723; SSF49723; 1.
DR   PROSITE; PS00711; LIPOXYGENASE_1; 1.
DR   PROSITE; PS00081; LIPOXYGENASE_2; 1.
DR   PROSITE; PS51393; LIPOXYGENASE_3; 1.
DR   PROSITE; PS50095; PLAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Dioxygenase; Iron;
KW   Lipid metabolism; Lipid-binding; Membrane; Metal-binding; Nucleus;
KW   Oxidoreductase; Polymorphism; Reference proteome.
FT   CHAIN         1    676       Arachidonate 15-lipoxygenase B.
FT                                /FTId=PRO_0000220700.
FT   DOMAIN        2    124       PLAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00152}.
FT   DOMAIN      125    676       Lipoxygenase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL        15     15       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:24497644}.
FT   METAL        17     17       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:24497644}.
FT   METAL        39     39       Calcium 2. {ECO:0000269|PubMed:24497644}.
FT   METAL        40     40       Calcium 2; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:24497644}.
FT   METAL        42     42       Calcium 2; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:24497644}.
FT   METAL        44     44       Calcium 2. {ECO:0000269|PubMed:24497644}.
FT   METAL        85     85       Calcium 1. {ECO:0000269|PubMed:24497644}.
FT   METAL        86     86       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:24497644}.
FT   METAL       373    373       Iron; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726,
FT                                ECO:0000269|PubMed:24497644}.
FT   METAL       378    378       Iron; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726,
FT                                ECO:0000269|PubMed:24497644}.
FT   METAL       553    553       Iron; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726,
FT                                ECO:0000269|PubMed:24497644}.
FT   METAL       676    676       Iron; via carboxylate; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00726,
FT                                ECO:0000269|PubMed:24497644}.
FT   VAR_SEQ     401    429       Missing (in isoform B and isoform D).
FT                                {ECO:0000303|PubMed:11839751}.
FT                                /FTId=VSP_003142.
FT   VAR_SEQ     483    527       Missing (in isoform B).
FT                                {ECO:0000303|PubMed:11839751}.
FT                                /FTId=VSP_003143.
FT   VAR_SEQ     561    617       FDSCAWMPNLPPSMQLPPPTSKGLATCEGFIATLPPVNATC
FT                                DVILALWLLSKEPGDQ -> VRKGQRPRWQAGGDPAPQPHS
FT                                ALSAFSLTPVLGCPTCHPACSCHHPPPKAWQHARAS (in
FT                                isoform C).
FT                                {ECO:0000303|PubMed:11839751}.
FT                                /FTId=VSP_003144.
FT   VAR_SEQ     618    676       Missing (in isoform C).
FT                                {ECO:0000303|PubMed:11839751}.
FT                                /FTId=VSP_003145.
FT   VARIANT     486    486       R -> H (in dbSNP:rs9895916).
FT                                {ECO:0000269|PubMed:11839751}.
FT                                /FTId=VAR_061334.
FT   VARIANT     656    656       Q -> R (in dbSNP:rs4792147).
FT                                {ECO:0000269|PubMed:11350124,
FT                                ECO:0000269|PubMed:11839751,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:9177185}.
FT                                /FTId=VAR_024524.
FT   VARIANT     676    676       I -> V (in dbSNP:rs7225107).
FT                                /FTId=VAR_024525.
FT   MUTAGEN      39     39       D->A: Abolishes calcium-dependent
FT                                association with membranes; when
FT                                associated with A-44 and A-85.
FT                                {ECO:0000269|PubMed:24497644}.
FT   MUTAGEN      44     44       E->A: Abolishes calcium-dependent
FT                                association with membranes; when
FT                                associated with A-39 and A-85.
FT                                {ECO:0000269|PubMed:24497644}.
FT   MUTAGEN      85     85       D->A: Abolishes calcium-dependent
FT                                association with membranes; when
FT                                associated with A-39 and A-44.
FT                                {ECO:0000269|PubMed:24497644}.
FT   MUTAGEN     602    602       D->Y: No effect on the stereoselectivity
FT                                of the oxygenation reaction. Completely
FT                                changes the stereoselectivity of the
FT                                oxygenation reaction to produce (8S)-
FT                                HPETE instead of (15S)-HPETE; when
FT                                associated with H-603.
FT                                {ECO:0000269|PubMed:10625675}.
FT   MUTAGEN     603    603       V->H: Changes the stereoselectivity of
FT                                the oxygenation reaction. Completely
FT                                changes the stereoselectivity of the
FT                                oxygenation reaction to produce (8S)-
FT                                HPETE instead of (15S)-HPETE; when
FT                                associated with Y-602.
FT                                {ECO:0000269|PubMed:10625675}.
FT   CONFLICT    271    271       V -> L (in Ref. 1; AAB61706 and 2;
FT                                CAC34521). {ECO:0000305}.
FT   CONFLICT    338    338       G -> C (in Ref. 6; AAD37786).
FT                                {ECO:0000305}.
FT   STRAND        3     10       {ECO:0000244|PDB:4NRE}.
FT   STRAND       20     30       {ECO:0000244|PDB:4NRE}.
FT   STRAND       50     56       {ECO:0000244|PDB:4NRE}.
FT   STRAND       63     72       {ECO:0000244|PDB:4NRE}.
FT   TURN         77     79       {ECO:0000244|PDB:4NRE}.
FT   STRAND       87     95       {ECO:0000244|PDB:4NRE}.
FT   STRAND      102    110       {ECO:0000244|PDB:4NRE}.
FT   STRAND      115    119       {ECO:0000244|PDB:4NRE}.
FT   TURN        126    128       {ECO:0000244|PDB:4NRE}.
FT   HELIX       132    148       {ECO:0000244|PDB:4NRE}.
FT   STRAND      161    163       {ECO:0000244|PDB:4NRE}.
FT   HELIX       167    169       {ECO:0000244|PDB:4NRE}.
FT   HELIX       172    174       {ECO:0000244|PDB:4NRE}.
FT   HELIX       178    197       {ECO:0000244|PDB:4NRE}.
FT   HELIX       212    215       {ECO:0000244|PDB:4NRE}.
FT   HELIX       216    219       {ECO:0000244|PDB:4NRE}.
FT   HELIX       223    231       {ECO:0000244|PDB:4NRE}.
FT   HELIX       235    244       {ECO:0000244|PDB:4NRE}.
FT   HELIX       265    272       {ECO:0000244|PDB:4NRE}.
FT   HELIX       278    284       {ECO:0000244|PDB:4NRE}.
FT   STRAND      287    291       {ECO:0000244|PDB:4NRE}.
FT   HELIX       293    295       {ECO:0000244|PDB:4NRE}.
FT   STRAND      314    319       {ECO:0000244|PDB:4NRE}.
FT   TURN        321    323       {ECO:0000244|PDB:4NRE}.
FT   STRAND      326    336       {ECO:0000244|PDB:4NRE}.
FT   HELIX       350    370       {ECO:0000244|PDB:4NRE}.
FT   TURN        371    373       {ECO:0000244|PDB:4NRE}.
FT   HELIX       374    377       {ECO:0000244|PDB:4NRE}.
FT   HELIX       379    391       {ECO:0000244|PDB:4NRE}.
FT   HELIX       397    402       {ECO:0000244|PDB:4NRE}.
FT   HELIX       403    406       {ECO:0000244|PDB:4NRE}.
FT   HELIX       409    419       {ECO:0000244|PDB:4NRE}.
FT   HELIX       426    430       {ECO:0000244|PDB:4NRE}.
FT   HELIX       434    446       {ECO:0000244|PDB:4NRE}.
FT   HELIX       451    454       {ECO:0000244|PDB:4NRE}.
FT   HELIX       456    462       {ECO:0000244|PDB:4NRE}.
FT   HELIX       472    495       {ECO:0000244|PDB:4NRE}.
FT   HELIX       499    503       {ECO:0000244|PDB:4NRE}.
FT   HELIX       506    518       {ECO:0000244|PDB:4NRE}.
FT   TURN        519    522       {ECO:0000244|PDB:4NRE}.
FT   HELIX       524    526       {ECO:0000244|PDB:4NRE}.
FT   HELIX       535    549       {ECO:0000244|PDB:4NRE}.
FT   HELIX       551    557       {ECO:0000244|PDB:4NRE}.
FT   HELIX       560    564       {ECO:0000244|PDB:4NRE}.
FT   HELIX       567    569       {ECO:0000244|PDB:4NRE}.
FT   STRAND      574    576       {ECO:0000244|PDB:4NRE}.
FT   STRAND      580    583       {ECO:0000244|PDB:4NRE}.
FT   HELIX       587    593       {ECO:0000244|PDB:4NRE}.
FT   HELIX       597    611       {ECO:0000244|PDB:4NRE}.
FT   HELIX       631    656       {ECO:0000244|PDB:4NRE}.
FT   HELIX       667    669       {ECO:0000244|PDB:4NRE}.
FT   STRAND      670    673       {ECO:0000244|PDB:4NRE}.
SQ   SEQUENCE   676 AA;  75857 MW;  4F641DF2F9D492C6 CRC64;
     MAEFRVRVST GEAFGAGTWD KVSVSIVGTR GESPPLPLDN LGKEFTAGAE EDFQVTLPED
     VGRVLLLRVH KAPPVLPLLG PLAPDAWFCR WFQLTPPRGG HLLFPCYQWL EGAGTLVLQE
     GTAKVSWADH HPVLQQQRQE ELQARQEMYQ WKAYNPGWPH CLDEKTVEDL ELNIKYSTAK
     NANFYLQAGS AFAEMKIKGL LDRKGLWRSL NEMKRIFNFR RTPAAEHAFE HWQEDAFFAS
     QFLNGLNPVL IRRCHYLPKN FPVTDAMVAS VLGPGTSLQA ELEKGSLFLV DHGILSGIQT
     NVINGKPQFS AAPMTLLYQS PGCGPLLPLA IQLSQTPGPN SPIFLPTDDK WDWLLAKTWV
     RNAEFSFHEA LTHLLHSHLL PEVFTLATLR QLPHCHPLFK LLIPHTRYTL HINTLARELL
     IVPGQVVDRS TGIGIEGFSE LIQRNMKQLN YSLLCLPEDI RTRGVEDIPG YYYRDDGMQI
     WGAVERFVSE IIGIYYPSDE SVQDDRELQA WVREIFSKGF LNQESSGIPS SLETREALVQ
     YVTMVIFTCS AKHAAVSAGQ FDSCAWMPNL PPSMQLPPPT SKGLATCEGF IATLPPVNAT
     CDVILALWLL SKEPGDQRPL GTYPDEHFTE EAPRRSIATF QSRLAQISRG IQERNQGLVL
     PYTYLDPPLI ENSVSI
//
